Accepted Manuscript

Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease

Andrew E. Hendifar, MD, MPH, Alberto M. Marchevsky, MD, Richard Tuli, MD, PhD

PII: \$1556-0864(16)33515-8

DOI: 10.1016/j.jtho.2016.11.2222

Reference: JTHO 437

To appear in: Journal of Thoracic Oncology

Received Date: 18 October 2016
Revised Date: 8 November 2016
Accepted Date: 10 November 2016

Please cite this article as: Hendifar AE, Marchevsky AM, Tuli R, Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease, *Journal of Thoracic Oncology* (2016), doi: 10.1016/j.jtho.2016.11.2222.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

1	Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and
2	Management of Well-Differentiated Disease
3	
4	Andrew E. Hendifar, MD, MPH ^a , Alberto M. Marchevsky, MD ^b , Richard Tuli, MD, PhD ^c
5	
6	^a Department of Medicine, ^b Department of Pathology and Laboratory Medicine, ^c Department of
7	Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California
8	
9	Address for correspondence: Andrew E. Hendifar, MD, MPH, Division of Hematology and
LO	Oncology, Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los
l 1	Angeles, CA 90033, USA. Phone: 310-423-2217. Fax: 310-659-3928. E-mail:
12	andrew.hendifar@cshs.org
L3	
L4	Disclosure: Dr. Hendifar reports compensation for serving on an advisory board for Novartis.
L5	Dr. Marchevsky and Dr. Tuli report no conflicts of interest.
L6	
L7	Funding Information: Financial support for editorial assistance was provided by Novartis
L8	Pharmaceuticals Corporation, in compliance with international guidelines on Good Publication
19	Practice.
20	
21	Short title: Advances in Lung Neuroendocrine Tumors

Download English Version:

https://daneshyari.com/en/article/5701924

Download Persian Version:

https://daneshyari.com/article/5701924

<u>Daneshyari.com</u>